Study Summary
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.
Interested in this trial?
Submit an InquiryInterventions
CYAD-02BIOLOGICAL
CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
ENDOXANDRUG
administered as preconditioning chemotherapy
FludaraDRUG
administered as preconditioning chemotherapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Mayo Clinic Cancer Center | Jacksonville | Florida | United States |
| University of Kansas Cancer Center | Fairway | Kansas | United States |
| Uz Leuven | Leuven | Belgium | |
| Chu Liege | Liège | Belgium | |
| AZ DELTA | Roeselare | Belgium |